Агонисты рецептора глюкагоноподобного пептида 1 как потенциальный путь преодоления резистентности к терапии при псориазе и псориатическом артрите

Пациенты с псориазом (ПсО) и псориатическим артритом (ПсА) характеризуются высокой частотой сопутствующего ожирения и метаболических нарушений, а увеличение индекса массы тела (ИМТ) повышает вероятность развития ПсА у пациентов с ПсО. Наличие ожирения, как и наличие ПсО/ПсА, ассоциируется с увеличением сердечно-сосудистого риска и ухудшением качества жизни. Достижение минимальной активности ПсО/ПсА у пациентов с ожирением может быть затруднено. Эффективное и стойкое снижение ИМТ (независимо от способа) ведет к увеличению вероятности наступления ремиссии и повышает эффективность ингибиторов фактора некроза опухоли α (ФНОα). В настоящем обзоре представлены результаты исследований влияния наиболее часто используемой группы препаратов для лечения ожирения – агонистов рецептора глюкагоноподобного пептида 1 на активность ПсО/ПсА, а также их комбинированного применения с генно-инженерными биологическими препаратами. 

1. Круглова ЛС, Бакулев АЛ, Коротаева ТВ и др. Псориаз. Москва: ГЭОТАР-Медиа; 2022. 328 с.

2. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017 Mar 9; 376(10):957-970. doi: 10.1056/NEJMra 1505557.

3. Scarpa R. Psoriatic Syndrome or Psoriatic Disease? J Rheumatol. 2020 Jun 1;47(6):941. doi: 10.3899/jrheum.200051.

4. Sheth S, Inestroza K, Merola JF, et al. Practical Recommendations on Cardiovascular Risk Evaluation in Patients With Psoriasis and Psoriatic Arthritis for Dermatologists, Rheumatologists, and Primary Care Physicians by the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network. J Psoriasis Psoriatic Arthritis. 2025 May 28; 10(4):124-130. doi: 10.1177/2475530 3251337020.

5. Reaven P. Metabolic syndrome. J Insur Med. 2004;36(2):132-42.

6. Kim SH, Reaven GM. The metabolic syndrome: one step forward, two steps back. Diab Vasc Dis Res. 2004 Oct;1(2):68-75. doi: 10.3132/dvdr.2004.010.

7. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006 Nov;55(5):829-35. doi: 10.1016/j.jaad.2006.08.040. Epub 2006 Sep 25.

8. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012 Dec 3;2(12):e54. doi: 10.1038/nutd.2012.26.

9. Snekvik I, Smith CH, Nilsen TIL, et al. Obesity, Waist Circumference, Weight Change, and Risk of Incident Psoriasis: Prospective Data from the HUNT Study. J Invest Dermatol. 2017 Dec;137(12): 2484-2490. doi: 10.1016/j.jid.2017.07.822.

10. Корсакова ЮЛ, Коротаева ТВ, Логинова ЕЮ и др. Клинико-инструментальная характеристика псориатического артрита у мужчин и женщин. Данные когортного наблюдательного исследования. Терапевтический архив. 2024;96(5):479-485.

11. Корсакова ЮЛ, Коротаева ТВ, Логинова ЕЮ и др. Взаимосвязь ожирения, кардиометаболических нарушений и активности заболевания у больных псориатическим артритом: данные Общероссийского регистра. Терапевтический архив. 2021;93(5):573-580.

12. Andreasson S, Södergren A. Prevalence of metabolic syndrome and its components in psoriatic arthritis compared with general population, cutaneous psoriasis, and other inflammatory arthropathies: a meta-analysis. Clin Rheumatol. 2025 Oct;44(10):3787-3799. doi: 10.1007/s10067-025-07637-z.

13. Czarnecka A, Purzycka-Bohdan D, Zablotna M, et al. Considerations of the Genetic Background of Obesity among Patients with Psoriasis. Genes (Basel). 2023 Feb 26; 14(3):594. doi: 10.3390/genes14030594.

14. Chiricozzi A, Raimondo A, Lembo S, et al. Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity. Expert Rev Clin Immunol. 2016 Dec; 12(12):1299-1308. doi: 10.1080/1744666X.2016.1201423.

15. Chiricozzi A, Gisondi P, Girolomoni G. The pharmacological management of patients with comorbid psoriasis and obesity. Expert Opin Pharmacother. 2019 May;20(7):863-872. doi: 10.1080/14656566.2019.1583207.

16. Takahashi H, Honma M, Ishida-Yamamoto A, Iizuka H. Adiponectin and leptin modulate cell proliferation and cytokine secretion of normal human keratinocytes and T lymphocytes. J Dermatol Sci. 2010 Aug; 59(2):143-5. doi: 10.1016/j.jdermsci.2010.06.004.

17. Jung MY, Kim HS, Hong HJ, et al. Adiponectin induces dendritic cell activation via PLC /JNK/NF-κB pathways, leading to Th1 and Th17 polarization. J Immunol. 2012 Mar 15;188(6):2592-601. doi: 10.4049/jimmunol.1102588.

18. Wang Y, Huo J, Zhang D, et al. Chemerin/ChemR23 axis triggers an inflammatory response in keratinocytes through ROS-sirt1-NF-κB signaling. J Cell Biochem. 2019 Apr;120(4):6459-6470. doi: 10.1002/jcb.27936.

19. Sluczanowska-Glabowska S, Staniszewska M, Marchlewicz M, et al. Adiponectin, Leptin and Resistin in Patients with Psoriasis. J Clin Med. 2023 Jan 13;12(2):663. doi: 10.3390/jcm12020663.

20. Chiricozzi A, Gisondi P, Girolomoni G. The pharmacological management of patients with comorbid psoriasis and obesity. Expert Opin Pharmacother. 2019 May;20(7):863-872. doi: 10.1080/14656566.2019.1583207.

21. Puig L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol. 2011 Sep;25(9):1007-11. doi: 10.1111/j.1468-3083.2011.04065.x.

22. Gisondi P, Cotena C, Tessari G, Girolomoni G. Anti-tumour necrosis factoralpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol. 2008 Mar;22(3):341-4. doi: 10.1111/j.1468-3083.2007.02429.x.

23. Jin D, Sun J, Huang J, et al. TNF-α reduces g0s2 expression and stimulates lipolysis through PPAR-γ inhibition in 3T3-L1 adipocytes. Cytokine. 2014 Oct;69(2):196-205. doi: 10.1016/j.cyto.2014.06.005.

24. Pina T, Genre F, Lopez-Mejias R, et al. Relationship of leptin with adiposity and inflammation and resistin with disease severity in psoriatic patients undergoing anti-TNF-alpha therapy. J Eur Acad Dermatol Venereol. 2015 Oct;29(10):1995-2001. doi: 10.1111/jdv.13131.

25. Di Minno MN, Peluso R, Iervolino S, et al. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers. Ann Rheum Dis. 2014 Jun;73(6):1157-62. doi: 10.1136/annrheumdis-2012-202812.

26. Klingberg E, Bilberg A, Björkman S, et al. Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study. Arthritis Res Ther. 2019 Jan 11;21(1):17. doi: 10.1186/s13075-019-1810-5.

27. Maglio C, Peltonen M, Rudin A, Carlsson LMS. Bariatric surgery and the incidence of psoriasis and psoriatic arthritis in the Swedish obese subjects study. Obesity (Silver Spring). 2017 Dec;25(12):2068-2073. doi: 10.1002/oby.21955.

28. Egeberg A, Sørensen JA, Gislason GH, et al. Incidence and prognosis of psoriasis and psoriatic arthritis in patients undergoing bariatric surgery. JAMA Surg. 2017 Apr 1; 152(4):344-349. doi: 10.1001/jamasurg.2016.4610.

29. Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Front Endocrinol (Lausanne). 2024 Jul 24:15:1431292. doi: 10.3389/fendo.2024.1431292.

30. Bajic Z, Sobot T, Uletilovic S, et al. Cardioprotective effects of liraglutide pretreatment on isoprenaline-induced myocardial injury in rats. Can J Physiol Pharmacol. 2023 May 1;101(5):258-267. doi: 10.1139/cjpp-2022-0534.

31. El-Shafey M, El-Agawy MSE, Eldosoky M, et al. Role of Dapagliflozin and Liraglutide on Diabetes-Induced Cardiomyopathy in Rats: Implication of Oxidative Stress, Inflammation, and Apoptosis. Front Endocrinol (Lausanne). 2022 Mar 18:13:862394. doi: 10.3389/fendo.2022.862394.

32. Zhao X, Wang M, Wen Z, et al. GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. Front Endocrinol (Lausanne). 2021 Aug 23:12:721135. doi: 10.3389/fendo. 2021.721135.

33. Насонов ЕЛ, Паневин ТС, Трошина ЕА. Агонисты рецепторов глюкагоноподобного пептида-1: перспективы применения в ревматологии. Научно-практическая ревматология. 2024;62(2):135-144.

34. Faurschou A, Pedersen J, Gyldenløve M, et al. Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques. Exp Dermatol. 2013 Feb;22(2):150-2. doi: 10.1111/exd.12081.

35. Atiquzzaman N, Razdolsky N, Parmar MS. GLP-1 receptor agonists: emerging therapeutic potential in psoriasis management – current evidence and future outlook. Eur J Clin Pharmacol. 2025 Nov;81(11):1569-1581. doi: 10.1007/s00228-025-03898-4.

36. Hogan AE, Tobin AM, Ahern T, et al. Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. Diabetologia. 2011 Nov;54(11):2745-54. doi: 10.1007/s00125-011-2232-3.

37. Buysschaert M, Tennstedt D, Preumont V. Improvement of psoriasis during exenatide treatment in a patient with diabetes. Diabetes Metab. 2012 Feb;38(1):86-8. doi: 10.1016/j.diabet.2011.11.004.

38. Faurschou A, Knop FK, Thyssen JP, et al. Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide. Acta Diabetol. 2014 Feb;51(1): 147-50. doi: 10.1007/s00592-011-0359-9.

39. Ahern T, Tobin AM, Corrigan M, et al. Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study. J Eur Acad Dermatol Venereol. 2013 Nov;27(11):1440-3. doi: 10.1111/j.1468-3083.2012.04609.x.

40. Buysschaert M, Baeck M, Preumont V, et al. Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal γδ T-cell number: a prospective caseseries study. Br J Dermatol. 2014 Jul;171(1): 155-61. doi: 10.1111/bjd.12886.

41. Xu X, Lin L, Chen P, et al. Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: A prospective cohort study. Diabetes Res Clin Pract. 2019 Apr:150:167-173. doi: 10.1016/j.diabres.2019.03.002.

42. Cai Y, Fleming C, Yan J. Dermal γδ T cells – a new player in the pathogenesis of psoriasis. Int Immunopharmacol. 2013 Jul; 16(3):388-91. doi: 10.1016/j.intimp.2013. 02.018.

43. Faurschou A, Gyldenløve M, Rohde U, et al. Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients-a randomized placebo-controlled trial. J Eur Acad Dermatol Venereol. 2015 Mar;29(3):555-9. doi: 10.1111/jdv.12629.

44. Chang G, Chen B, Zhang L. Efficacy of GLP-1rA, liraglutide, in plaque psoriasis treatment with type 2 diabetes: a systematic review and meta-analysis of prospective cohort and before-after studies. J Dermatolog Treat. 2022 May;33(3):1299-1305. doi: 10.1080/09546634.2021.1882658.

45. Nicolau J, Nadal A, Sanchis P, et al. Effects of liraglutide among patients living with psoriasis and obesity. Med Clin (Barc). 2023 Oct 13;161(7):293-296. doi: 10.1016/j.medcli.2023.05.021.

46. Коротаева ТВ, Трошина ЕА, Лила АМ и др. Эффективность лираглутида в комплексной терапии больных псориазом в сочетании с метаболическими нарушениями: метаанализ наблюдательных и контролируемых исследований. Ожирение и метаболизм. 2025;22(2):70-76.

47. Nicolau J, Nadal A, Sanchis P, et al. Effects of six months treatment with liraglutide among patients with psoriasis and obesity, beyond metabolic control? Med Clin (Barc). 2025 Jun 13;164(11):106941. doi: 10.1016/j.medcli.2025.106941.

48. Lin L, Xu X, Yu Y, et al. Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial. J Dermatolog Treat. 2022 May;33(3):1428-1434. doi: 10.1080/09546634.2020.1826392.

49. Nicolau J, Nadal A, Ros I, Masmiquel L. Effects of liraglutide among patients with psoriatic arthritis and obesity. Reumatol Clin (Engl Ed). 2025 Jan;21(1):501809. doi: 10.1016/j.reumae.2025.501809.

50. Costanzo G, Curatolo S, Busа B, et al. Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient. Endocrinol Diabetes Metab Case Rep. 2021 Aug 1:2021:21-0007. doi: 10.1530/EDM-21-0007.

51. Malavazos AE, Meregalli C, Sorrentino F, et al. Semaglutide therapy decreases epicardial fat inflammation and improves psoriasis severity in patients affected by abdominal obesity and type-2 diabetes. Endocrinol Diabetes Metab Case Rep. 2023 Aug 8;2023(3):23-0017. doi: 10.1530/EDM-23-0017.

52. Nicolau J, Nadal A, Sanchis P, et al. Dermatological and metabolic benefits of semaglutide in psoriasis with obesity: a 6-month prospective cohort study. Clin Exp Dermatol. 2026 Feb 24;51(3):442-450. doi: 10.1093/ced/llaf473.

53. Petkovic-Dabi J, Binic I, Caric B, et al. Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial. Biomolecules. 2025 Jan 1; 15(1):46. doi: 10.3390/biom15010046.

54. Gisondi P, Brigenti N, Bellinato F, Girolomoni G. Tirzepatide in obese patients with psoriasis on biological therapy: Is this a window of opportunity? J Eur Acad Dermatol Venereol. 2026 Jun;40(6):e460-e462. doi: 10.1111/jdv.70208.

55. Круглова ЛС, Бридан-Ростовская АС, Шатохина ЕА. Опыт применения Нетакимаба и агониста ГПП1 у пациентов с псориазом и метаболическим синдромом. Медицинский алфавит. 2026;(3):28-34.

56. Currado D, Trunfio F, Saracino F, et al. Patients with psoriatic arthritis and comorbid metabolic syndrome show a difficult-to-treat phenotype: another mosaic tile in the definition of a still undefined subset of patients. RMD Open. 2025 Jun 22;11(2):e005717. doi: 10.1136/rmdopen-2025-005717.

57. Merola JF, Mease P, Kivitz A, et al. Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial. Arthritis Rheumatol. 2026 Mar 28. doi: 10.1002/art.70134. Online ahead of print.

58. Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017 Jan;76(1):79-87. doi: 10.1136/annrheumdis-2016-209709.